Case Report

Five Cases of Non-Hodgkin B-Cell Lymphoma of the Ovary

Taylan Senol, Emek Doger, Ilker Kahramanoglu, Ayfer Geduk, Emre Kole, Izzet Yucesoy, and Eray Caliskan

1 Department of Obstetrics and Gynecology, Kocaeli University Medical Faculty, Kocaeli, Turkey
2 Suleymaniye Gynaecologic and Obstetrics Training and Research Hospital, Department of Gynecology, Istanbul, Turkey
3 Department of Hematology/Oncology, Kocaeli University Medical Faculty, Kocaeli, Turkey

Correspondence should be addressed to Ilker Kahramanoglu; ilkerkahramanoglu@hotmail.com

Received 19 September 2013; Accepted 2 December 2013; Published 22 January 2014

Copyright © 2014 Taylan Senol et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The involvement of the ovary in lymphomatous process is rare. Such an involvement may occur in 2 ways, primary or secondary. We report 5 cases of ovarian non-Hodgkin's lymphoma, with 3 of which primarily arising in the ovaries. Ovarian lymphoma can mimic more frequently occurring tumors including advanced epithelial carcinoma and radical surgery may be performed instead of a biopsy. The immunophenotypic and clinicopathologic features exhibited in this small series are described to call attention to early diagnosis and treatment of ovarian lymphoma. All patients were diagnosed as having DLBCL after ovarian biopsy. Different treatment modalities were used and prognosis of the patients was reported.

1. Introduction

Involvement of the ovary by malignant lymphoma, particularly Non-Hodgkin's lymphoma (NHL), is a well-known manifestation of disseminated lymphoma with a frequency of 7% to 26% [1]. However, presumably primary ovarian Non-Hodgkin's lymphoma (PONHL) is rare and accounts for 0.5% of NHL and 1.5% of ovarian tumors [2]. Diffuse large B-cell type accounts for about 20% of PONHL [3]. All of the cases presented in this report were diffuse large B-cell lymphoma. Primary ovarian lymphoma (POL) may be misdiagnosed as epithelial ovarian malignancy. This report describes 5 cases of ovarian NHL, with 3 of which primarily arising in the ovaries. The immunophenotypic and clinicopathologic features exhibited in this small series are described to call attention to early diagnosis and treatment of ovarian lymphoma.

2. Case 1

A 65-year-old, vaginally grand multiparous woman presented to our clinic with symptoms of night sweats and fatigue for a year. She reported 21 kilogram weight loss over the past year. She had no significant medical or family history and she had used no medications. Physical examination revealed a large, palpable, nontender mass with restricted mobility in both lower quadrants up to the level of the umbilicus. A low platelet count was detected, a level of $114 \times 10^3 \mu\text{L}$ (the reference level: $142 \times 10^3 \mu\text{L}$). Serum CA 125 and lactate dehydrogenase (LDH) were raised (541U/mL and 821IU/L, resp.), but CA 19-9 and CEA were within normal limits. Transabdominal ultrasonography demonstrated a complex adnexal mass, measuring $12.5 \times 11 \text{ cm}$ with solid areas and internal echoes. A computer tomography (CT) scan revealed an $11 \times 9 \times 7 \text{ cm}$, solid, left ovarian mass with ascites (Figure 1). The patient underwent surgery with the presumed diagnosis of an ovarian malignancy. At laparotomy, about 2 liters of gelatinous floating material was scooped out of the peritoneal cavity. A $20 \times 15 \text{ cm}$ pelvic mass, originating from the left adnexal area, adherent to descending colon was found. No definite metastatic lesion was observed. The mass was removed completely, the left ureter was identified, intraoperative frozen section was performed, and a poorly differentiated hematological malignancy was diagnosed. The surgery included hysterectomy and bilateral salpingooophorectomy along with omentectomy, pelvic and inguinal lymph node sampling, appendectomy, peritoneal cytology, and peritoneal biopsy.
A 61-year-old, grand multiparous woman presented to our clinic with symptoms of fatigue and progressive abdominal swelling of 3 months. She had a history of hypertension and asthma diagnosed five years ago. Upon examination, a large abdomino-pelvic mass with restricted mobility was detected. Laboratory studies showed elevated levels of CA125 and LDH, 312 U/mL and 417 IU/L, respectively. Other laboratory tests, including CA 19-9 and CEA, were within normal limits. Ultrasonography showed a large amount of free fluid in the cul-de-sac, a left adnexal solid mass measuring 10 × 6 cm, and a right adnexal solid mass measuring 6 × 5 cm, and those were confirmed on a CT scan. Exploratory laparotomy revealed a 10 cm right-sided and 8 cm left-sided solid masses and 15 cm retroperitoneal mass localized in front of the aorta and below the kidneys. At the time of the surgery, 3 L of ascites was evacuated. There were multiple implants ranging from 1 cm to 5 cm on the surface of peritoneum. Frozen section of the resected masses demonstrated a poorly differentiated malignant lesion. A total hysterectomy and bilateral salpingooophorectomy along with omentectomy, lymph node sampling, appendectomy, peritoneal cytology, and peritoneal biopsy were performed. Immunohistochemical evaluation showed strong staining for CD20. These same cells were negative for pan-cytokeratin, S-100, EMA, CD30, CD10, CD5, HMB-45, and inhibin. Bone marrow biopsy showed no evidence of malignant cells. The diagnosis of diffuse large B-cell lymphoma was made and stage was assessed as IV BE according to the Ann Arbor system. After operation, MRI scans showed para-aortic and paracaval bulky lymph nodes. A chemotherapy protocol comprising 6 cycles of R-CHOP regimen was administered to the patient. Radiation therapy was also given for retroperitoneal mass. Followup to 6 months after surgery showed no evidence of recurrence.
Case Reports in Obstetrics and Gynecology

Figure 2: Diffuse infiltration of malignant lymphoid cells (H&E ×100) (a) stained with CD20 (b) and bcl-2 (c) (immunohistochemistry ×40 and ×100, resp.).

6. Case 5
A 57-year-old grand multiparous woman presented to our clinic with a history of abdominal swelling, night sweats, and fatigue of 2 months. She had no significant medical or family history. Upon examination, a tender mass of 24-week size with restricted mobility was detected. CT scan revealed a 16 × 15 × 10 cm left ovarian mass with ascites (Figure 3). Laboratory studies showed elevated levels of CA125 and LDH, 220 U/mL and 2012 IU/L, respectively. A biopsy of the mass was performed. Immunohistochemical evaluation showed strong staining for CD20 but was negative for CD5 and CD10. The diagnosis of stage I BE and diffuse large B-cell lymphoma was made. Bone marrow biopsy showed no evidence of malignant cells. Chemotherapy could not be started because of her poor general condition and the patient died in a month.

7. Discussion
Ovarian involvement by malignant lymphoma is well recognized and is seen at autopsy with a frequency of 7%–26% [1]. However, POL as the initial manifestation is an uncommon entity, accounting for 0.5% of all non-Hodgkin’s lymphoma and 1.5% of all ovarian neoplasms [2]. POL can mimic more frequently occurring tumors including advanced epithelial carcinoma as in cases 1, 2, and 3, and, therefore, the correct diagnosis and optimal treatment would have been missed without histopathological examination [4]. These
### Table 1: Details of 5 cases of ovarian NHL, presented in this report.

| Patient number | Age | Presentation | Size and side | Immunophenotype | Histologic type | Ann Arbor stage | Therapy | Follow up |
|----------------|-----|--------------|---------------|-----------------|----------------|----------------|---------|-----------|
| 1              | 65  | 21kg weight loss, night sweats, fatigue | 20 × 15 cm left ovarian mass | CD20 (+), bcl-2 (+) pan-cytokeratin (−) S-100 (−) EMA (−) CD30 (−) HMB-45 (−) inhibin (−) | DLBCL | I BE | Sx | Developed multiorgan failure; died of disease 1 month after operation |
| 2              | 61  | Abdominal swelling, fatigue | 20 × 12 cm right ovarian mass | CD20 (+) CD45 (+) bcl-2 (+) Ki-67 (+) CD3 (−) | DLBCL | I BE | Sx, CT | Died from pneumonia at the 20th postoperative month |
| 3              | 53  | Abdominal swelling, night sweats, frequent urination, increasing pain in the abdomen | 10 × 8 cm right ovarian mass, 8 × 8 cm left ovarian mass, and 15 × 13 cm retroperitoneal mass in front of the aorta | CD20 (+) bcl-2 (+) pan-cytokeratin (−) S-100 (−) EMA (−) CD30 (−) CD10 (−) CD5 (−) HMB-45 (−) inhibin (−) | DLBCL | IV BE | Sx, CT, RT | 6 months after surgery, alive with no evidence of recurrence |
| 4              | 52  | Abdominal swelling, fatigue | 16 × 10 cm right ovarian mass | CD20 (+) bcl-2 (+) CD5 (−) CD3 (−) | DLBCL | I BE | CT | 12 months after chemotherapy, alive with no evidence of recurrence |
| 5              | 57  | Abdominal swelling, fatigue, night sweats | 16 × 10 cm left ovarian mass | CD20 (+) bcl-2 (+) CD5 (−) CD10 (−) | DLBCL | I BE | — | Rapidly developed multiorgan failure; died of disease in a month |

DLBCL: diffuse large B-cell lymphoma; Sx: surgery; CT: chemotherapy (rituximab, cyclophosphamide, hydroxydaunorubicin, Oncovin, prednisolone (R-CHOP)); RT: radiotherapy. F-FDG PET/CT: 18-fluorodeoxyglucose positron emission computerized tomography.
three patients underwent radical surgery with the presumed diagnosis of an epithelial ovarian malignancy, whereas right diagnosis could allow optimal treatment, which is chemotherapy, instead of radical surgery.

Lymphomas of the ovary can occur at any age, but most often in women over the age of 40 (mean, 47 years old in 8 presented cases) [5]. Our patients ranged in age from 52 to 65 years (mean 57 years) (Table 1). Lymphomas of the ovary may have varied presentations such as abdominal pain, pelvic mass, and ascites. Fever, night sweats, fatigue, or weight loss (B symptoms) was noted in 10%–33% of the patients [2, 3]. In our study, 4 of 5 cases presented with an abdominal mass. All of the patients had B symptoms of NHL.

It is difficult to determine whether ovarian lymphomas are primary or secondary. There has been much controversy in the histogenesis of POL. It is demonstrated that normal ovaries contain lymphocytes of B-cell and T-cell lineage within cortical granulomas and rare lymphocytes are present throughout the ovarian stroma and within ovarian follicles and corpora lutea, which can be the source of NHL [1]. Fox et al. proposed the following criteria for the diagnosis of PONHL [6]. (1) At the time of diagnosis, the lymphoma is clinically confined to the ovary and a complete investigation fails to reveal evidence of lymphoma elsewhere. However, an ovarian lymphoma can still be considered as primary if it has spread to immediately adjacent lymph nodes or if it has directly spread to infiltrate immediately adjacent structures. (2) The peripheral blood and bone marrow should not contain any abnormal cells. (3) If further lymphomatous lesions occur at sites remote from the ovary, then at least several months should have elapsed between the appearance of the ovarian and extranodal lesions. When these criteria are applied, cases 2, 4, and 5 in our report can be diagnosed as PONHL. Although bone marrow biopsy could not be performed because of the patient's poor general condition in case 1, the lymphoma was confined to the ovary as seen on MRI and in surgery. So, lymphoma in case 1 also can be considered as primary ovarian. Diffuse large B-cell lymphoma is the most common subtype of NHL and appears to be the most common type of primary ovarian [5]. All of cases in this report had diffuse large B-cell lymphoma and immunohistochemical evaluation showed strong straining for CD20 for all of them. In case 2, tumour cells were also positive for CD 45 and Ki-67. Patients with ovarian lymphomas are treated with chemotherapy. Radiotherapy is optional [7]. The protocol for chemotherapy used in diffuse large B-cell histology is the standard R-CHOP regimen. Rituximab plays an essential role in treatment of CD20-positive B-cell lymphoma [8]. PONHLs have a poor outcome with a range from 0% to 36% expected to survive for less than three years [2, 9].

In conclusion, prognosis of ovarian lymphomas is often poorer than nodal lymphomas because of delayed or inaccurate diagnosis. The best treatment option seems to be chemotherapy. Physicians should be aware of this rare presentation to avoid radical surgery, which is unnecessary.

Conflict of Interests
The authors declare that they have no conflict of interests regarding the publication of this paper.

References
[1] I. Chorlton, H. J. Norris, and F. M. King, “Malignant reticuloendothelial disease involving the ovary as a primary manifestation. A series of 19 lymphomas and 1 granulocytic sarcoma,” Cancer, vol. 34, no. 2, pp. 397–407, 1974.
[2] M. A. Dimopoulos, D. Daliani, W. Pugh, D. Gershenson, F. Cabanillas, and A. H. Sarris, “Primary ovarian non-Hodgkin’s lymphoma: outcome after treatment with combination chemotherapy,” Gynecologic Oncology, vol. 64, no. 3, pp. 446–450, 1997.
[3] V. Monterroso, E. S. Jaffe, M. J. Merino, and L. J. Medeiros, “Malignant lymphomas involving the ovary: a clinicopathologic analysis of 39 cases,” American Journal of Surgical Pathology, vol. 17, no. 2, pp. 154–170, 1993.
[4] A. S. Weingertner, D. Hamid, M. N. Roedlich, and J. J. Baldauf, “Non-Hodgkin malignant lymphoma revealed by an ovarian tumor: case report and review of the literature,” Gynecologic Oncology, vol. 95, no. 3, pp. 750–754, 2004.
[5] R. Vang, L. J. Medeiros, R. A. Warnke, J. P. Higgins, and M. T. Deavers, “Ovarian non-Hodgkin’s lymphoma: a clinicopathologic study of eight primary cases,” Modern Pathology, vol. 14, no. 11, pp. 1093–1099, 2001.
[6] H. Fox, F. A. Langley, A. D. T. Govan, S. A. Hill, and M. H. Bennett, “Malignant lymphoma presenting as an ovarian tumour: a clinicopathological analysis of 34 cases,” British Journal of Obstetrics and Gynaecology, vol. 95, no. 4, pp. 386–390, 1988.
[7] N. Sakurai, K. Tateoka, J. Taguchi, and T. Terada, “Primary precursor B-cell lymphoblastic lymphoma of the ovary: case report and review of the literature,” International Journal of Gynecological Pathology, vol. 27, no. 3, pp. 412–417, 2008.
[8] P. Feugier, A. Van Hoof, C. Sebben et al., “Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe detude des lymphomes de l’adul,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4117–4126, 2005.
[9] R. Hu, M. Miao, R. Zhang et al., “Ovary involvement of diffuse large B-cell lymphoma,” The American Journal of Case Reports, vol. 13, pp. 96–98, 2012.